Systemic lupus erythematosus
Last Updated: 2026-11-20
Author(s): Anzengruber F., Navarini A.
ICD11: 4A40.0Z
Cite
Permalink
Publication History
Version 1
12 October 2023
Version 2
20 November 2026
SLE, lupus erythematosus integumentalis, lupus erythematosus visceralis, visceral lupus erythematosus.
Potentially fatal, chronic inflammatory, relapsing autoimmune disease of vascular connective tissue with cutaneous and visceral involvement. Autoantibodies against double-stranded DNA are characteristic.
-
Prevalence: 40 / 100,000.
-
Incidence: 5-10 / 100,000 / year.
-
4 times more common in Africans than in Caucasians or Asians.
-
Familial clustering: in approximately 10%.
-
Severity: more severe courses are often observed in people of Spanish–South American and African American ancestry.
-
Women:men = 8-10:1.
-
Patients are rarely younger than 5 years.
-
Onset is usually in young adulthood (15–30 years), although late-onset SLE is possible.
-
Acute cutaneous lupus erythematosus
-
Systemic lupus erythematosus with organ involvement
-
Drug-induced lupus erythematosus
-
Neonatal lupus erythematosus
-
Multifactorial aetiology and triggers.
-
UV radiation.
-
Genetics (e.g. TREX1 gene mutation, association with HLA-DR3 (in Caucasians), HLA-DR1 and -DR2 (in Asians)).
-
Drugs (see drug-induced lupus erythematosus).
-
Oestrogens (e.g. exacerbation during pregnancy).
-
Viral infections.
-
CD4+ T lymphocytes secrete IL-4 & 6, leading to B-cell activation, subsequent autoantibody production and, more broadly, immune complex formation. Circulating immune complexes may deposit in small vessels of visceral organs or the skin, where they may trigger vasculitis. Immune complexes may also form in the basement membrane.
-
General symptoms: ↑ temperature, fatigue, weight loss.
-
Skin (in approximately 80% of patients)
-
Face: erythema perstans (scaly, poorly demarcated butterfly erythema); in some cases, the entire face may be affected. Approximately 60% of all patients with SLE have butterfly erythema.
-
Trunk: multiform or livedoid eruptions of the upper trunk, often haemorrhagic, rarely bullous. 20-30% of patients have SCLE- or DLE-like skin lesions. Up to 20% of patients remain free of skin manifestations.
-
Palms and soles: patchy, diffuse, partly keratotic erythema.
-
Livedo racemosa.
-
Telangiectasia of the fingertips and subungual haemorrhages at the nail fold.
-
Vasculitic changes may cause pain, gangrene and ulceration.
-
Oral mucosa (in approximately 40% of patients): enanthema, erosions, ulceration.
-
Lips: cheilitis
-
Myalgia (almost all patients).
-
Arthritis (almost all patients), usually without visible swelling. An additional polyarthritis occurs in 10%.
-
Serositis (approximately 50% of patients): pleuritis, pericarditis (Libman–Sacks endocarditis is a separate manifestation) or peritonitis.
-
Lupus nephritis or nephrotic syndrome (in approximately 40–65% of patients).
-
Lymphadenopathy.
-
Hepatosplenomegaly.
-
Gastritis.
-
Colitis.
-
Psychoses.
-
Seizures.
-
Scarring alopecia.
-
Raynaud phenomenon.
-
Associations:
-
Sweet syndrome.
-
Livedoid vasculopathy.
-
-
Anti-dsDNA titres and complement may support activity assessment, but clinical findings and organ screening guide decisions.
-
Autoantibodies against double-stranded DNA and immune complexes with complement activation, which may trigger vasculitis in various organs.
The 2019 EULAR / ACR criteria below support research classification, not exclusion of a clinical diagnosis.
Investigate suspected organ involvement regardless of classification score.
2019 EULAR / ACR classification criteria for SLE
Entry criterion: ANA ≥1:80 on HEp-2 cells, or an equivalent positive test, documented at least once. If absent, these criteria cannot classify the patient as SLE; this does not exclude a clinical diagnosis.
Scoring rules
Count a criterion only when no more likely explanation than SLE exists.
A criterion documented on one occasion is sufficient; criteria need not occur simultaneously.
Within each domain, count only the highest-scoring criterion.
Classification requires at least one clinical criterion and a total of ≥10 points, after the entry criterion is met.
Clinical criteria
Domain | Criterion | Points |
|---|---|---|
Constitutional | Fever | 2 |
Haematological | Leucopenia | 3 |
Haematological | Thrombocytopenia | 4 |
Haematological | Autoimmune haemolysis | 4 |
Neuropsychiatric | Delirium | 2 |
Neuropsychiatric | Psychosis | 3 |
Neuropsychiatric | Seizure | 5 |
Mucocutaneous | Non-scarring alopecia | 2 |
Mucocutaneous | Oral ulcers | 2 |
Mucocutaneous | Subacute cutaneous OR discoid lupus | 4 |
Mucocutaneous | Acute cutaneous lupus | 6 |
Serosal | Pleural or pericardial effusion | 5 |
Serosal | Acute pericarditis | 6 |
Musculoskeletal | Joint involvement | 6 |
Renal | Proteinuria >0.5 g/24 h | 4 |
Renal | Renal biopsy: class II or V lupus nephritis | 8 |
Renal | Renal biopsy: class III or IV lupus nephritis | 10 |
Immunological criteria
Domain | Criterion | Points |
|---|---|---|
Antiphospholipid antibodies | Anticardiolipin antibodies OR anti-β₂-glycoprotein I antibodies OR lupus anticoagulant | 2 |
Complement proteins | Low C3 OR low C4 | 3 |
Complement proteins | Low C3 AND low C4 | 4 |
SLE-specific antibodies | Anti-dsDNA antibodies* OR anti-Smith (Sm) antibodies | 6 |
* Anti-dsDNA assay requirement: demonstrated specificity ≥90% for SLE against relevant disease controls.
Total score: sum the highest score from each applicable domain. ≥10 points plus at least one clinical criterion and the ANA entry criterion fulfils classification.
Source: 2019 EULAR / ACR classification criteria.
Figure link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6827566/figure/F2/
ANAs in SLE
Antigen | Frequency |
|---|---|
Native DNA | 50-90% |
U1-RNP (nuclear) | 30-60% |
Sm | 10-30% |
rRNP (ribosomal) | 10% |
Ro(SSA) | 40-60% |
La(SSB) | 20-30% |
Ku | 10% |
Histones | 70% |
Source: Plewig, Gerd. Braun-Falco's Dermatologie, Venerologie Und Allergologie. Berlin: Springer, 2012. Print.
CAUTION:
False-positive Rh factor (in approximately 33%)
False-positive syphilis serology (VDRL) (in approximately 25%).
Dermatopathology and direct immunofluorescence.
Dermatopathology
Interface dermatitis, perivascular lymphocytic, oedematous infiltrate.
Direct immunofluorescence
Lupus band test: band-like granular deposits of IgG, C3 (also IgM and IgA) along the basement membrane (also in non-lesional, unexposed skin).
Phototesting
Graded light exposure, followed by photoprovocation.
Baseline assessment and symptom-directed investigations (lumbar puncture, EEG, angiography and other invasive tests are not routine screening):
Blood pressure and temperature measurement.
Urinalysis:
Urinalysis with sediment, urine protein / creatinine ratio and serum creatinine / eGFR; quantify proteinuria and refer for suspected nephritis.
Chest X-ray.
Lung function including gas transfer when indicated; normal results do not exclude early ILD, and suspected disease may require HRCT.
X-ray or ultrasound of painful joints.
Upper abdominal ultrasound.
Renal biopsy: lupus nephritis.
Echocardiography: carditis.
Capillaroscopy.
Lumbar puncture.
EEG.
Gadolinium-enhanced MRI, MR angiography, angiography: if cerebral vasculitis is suspected.
Ophthalmological assessment: conjunctivitis, sicca symptoms.
Systemic lupus erythematosus (SLE) commonly affects the skin, mucous membranes, joints and internal organs. Typical skin manifestations include facial butterfly erythema and involvement of other sun-exposed areas such as the upper chest and arms. The oral and nasal mucosae are often affected, with enanthema, erosions and occasional ulceration; the lips may develop cheilitis. Joint involvement usually presents as non-erosive arthritis, predominantly affecting small joints without marked swelling.
Interface dermatitis with a lymphocytic infiltrate at the dermoepidermal junction. A band-like infiltrate along the basement membrane, accompanied by vacuolar degeneration of basal cells, is characteristic. Histology frequently shows perivascular and periadnexal lymphocytic infiltrates and oedema in the upper dermis. Another feature is immune complex deposition (IgG, IgM, IgA and C3) along the basement membrane, detectable by direct immunofluorescence in the lupus band test – often also in non-lesional, untreated skin.
One of the most serious complications is lupus nephritis, which may lead to chronic renal failure and, in advanced cases, dialysis dependence. Cardiovascular complications, including pericarditis, myocarditis and an increased risk of atherosclerosis, are also common. Neurologically, SLE may cause seizures, psychoses and cognitive impairment. Haematological complications include haemolytic anaemia, thrombocytopenia and an increased risk of thrombosis due to antiphospholipid antibodies. Interstitial lung disease, pleuritis and an increased risk of infection due to immunosuppressive therapies may also occur.
-
Chronic, relapsing course.
-
The disease may be fatal, depending on organ involvement.
Prophylaxis in systemic lupus erythematosus (SLE) focuses on preventing flares and reducing the risk of progression. Consistent UV protection is essential, as sun exposure often triggers exacerbations; daily high-SPF sunscreen and protective clothing are recommended. Avoiding known triggers such as certain drugs and nicotine is also essential, as these may adversely affect the disease course. Regular assessment of cardiovascular risk factors is important, as patients with SLE have an increased risk of atherosclerosis and thrombosis. Women of childbearing age should plan pregnancy with their treating doctor to minimise flares during pregnancy.
Hydroxychloroquine is baseline therapy unless contraindicated, usually targeting ≤5 mg/kg/day actual body weight with individualisation and retinal screening. Use glucocorticoids as short-term bridging treatment; reduce maintenance prednisone equivalent to ≤5 mg/day and withdraw when possible, introducing steroid-sparing therapy early. For moderate activity without organ-threatening disease, additional options include methotrexate, mycophenolate or azathioprine. Skin manifestations are additionally treated with topical glucocorticoids and / or calcineurin inhibitors; facial glucocorticoid use should be time-limited because of the risk of atrophy. For persistent moderate to severe skin involvement despite topical therapy and antimalarials, methotrexate, mycophenolate, anifrolumab or belimumab may be added. Selection takes account of scarring risk, comorbidities and patient preference; direct comparative studies between the two biologics are lacking. Organ- or life-threatening flares require immediate intensive treatment. High-dose glucocorticoids with intravenous cyclophosphamide and / or rituximab are options for remission induction in organ- or life-threatening non-renal SLE caused by disease activity. Lupus nephritis needs rheumatology–nephrology planning by histology and risk; mycophenolate / low-dose cyclophosphamide-based regimens may incorporate belimumab or a calcineurin inhibitor. Check pregnancy safety before immunosuppression.
In life-threatening SLE vasculitis, such as diffuse alveolar haemorrhage or mesenteric vasculitis, plasma exchange and / or intravenous immunoglobulin may be considered in addition to high-dose glucocorticoids and immunosuppression. This is a conditional recommendation based on very low-certainty evidence.
Belimumab and anifrolumab are licensed add-on SLE therapies in Switzerland and the EU, including Germany / Austria, within their respective disease-activity, age and formulation criteria. Anifrolumab should not be extrapolated to severe active lupus nephritis or severe active CNS lupus, where efficacy is not established. Rituximab and several conventional immunosuppressive regimens may be guideline-supported off-label choices; a recommendation is not itself a national product indication. For nephritis, select the actual combination: voclosporin is used with mycophenolate and glucocorticoids, not as an interchangeable addition to cyclophosphamide.
Swaak A, van H, Smeenk R, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus. 2001;10:51-8.
Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. The Lancet. 2002;359:579-80.
Roman MJ, Shanker B-A, Davis A, et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. N Engl J Med. 2003;349:2399-406.
Al-Raqum HA, Uppal SS, Al-Mutairy M, Kumari R. Shrinking lung syndrome as a presenting manifestation of systemic lupus erythematosus in a female Kuwaiti. Clin Rheumatol. 2005;25:412-4.
Petri M, Kim MY, Kalunian KC, et al. Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. N Engl J Med. 2005;353:2550-8.
Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in Systemic Lupus Erythematosus. Medicine. 2006;85:95-104.
Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials—an interim analysis. Nat Rev Rheumatol. 2009;5:348-51.
Tassiulas IO, Boumpas DT. Clinical Features and Treatment of Systemic Lupus Erythematosus. Kelley's Textbook of Rheumatology: Elsevier BV;2009:1263-300.
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52.
Almoallim H, Khadawardi H. Anti-Tumour Necrosis Factor-α Induced Systemic Lupus Erythematosus. Systemic Lupus Erythematosus: InTech;2012.
Takayama A, Ishiguro N, Kawashima M. Coexistence of Bowenoid papulosis and Bowen's disease in a patient with systemic lupus erythematosus. J Dermatol. 2012;39:646-9.
Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral Neuropathies in Systemic Lupus Erythematosus: Clinical Features, Disease Associations, and Immunologic Characteristics Evaluated Over a Twenty-Five-Year Study Period. Arthritis & Rheumatology. 2014;66:1000-9.
Soudet S, Delaporte E, Hatron PY. Diffuse calcinosis cutis in systemic lupus erythematosus: an exceptional complication. Lupus 2016.
Tenbrock K. (2016). S1- Leitlinie: Systemischer Lupus erythematodes. Awmf.org. Retrieved 30 May 2016, from. Available online.
Wallace D. (2016). Overview of the management and prognosis of systemic lupus erythematosus in adults. Uptodate.com. Retrieved 30 May 2016, from. Available online.
Aringer M. EULAR / ACR classification criteria for SLE. Semin Arthritis Rheum. 2019 Dec;49(3S). Review. doi:10.1016/j.semarthrit.2019.09.009; PMID: 31779843.
Abdalhadi HM, Chatham WW, Alduraibi FK. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview. Int J Mol Sci. 2024 Sep 29;25(19):10511. Free PMC article. Review. doi:10.3390/ijms251910511; PMID: 39408836.
Ghodke-Puranik Y, Olferiev M, Crow MK. Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy. Nat Rev Rheumatol. 2024 Oct;20(10):635-648. Epub 2024 Sep 4. Review. doi:10.1038/s41584-024-01152-2; PMID: 39232240.
Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. 2024. doi:10.1136/ard-2023-224762.
Sammaritano LR, et al. 2025 American College of Rheumatology Guideline for the Treatment of Systemic Lupus Erythematosus. 2025. doi:10.1002/acr.25690.
Md Yusof MY, et al. The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus. 2026. Available online.
Swissmedic. Public Summary SwissPAR: Saphnelo (anifrolumab). 2022. Available online.
EMA. Saphnelo (anifrolumab): EPAR and product information. 2026. Available online.
EMA. Benlysta (belimumab): EPAR and product information. 2026. Available online.
BAG. Lupkynis: reimbursement assessment with Swiss authorised indication and combination restrictions. 2024. Available online.
This website uses cookies!
We use cookies to tailor our content to your needs and continuously improve our website. You can decide which cookies you want to allow. Detailed information about the cookies we use can be found in our Privacy Policy and Cookie Settings. You can withdraw your consent at any time.